Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 3
2013 1
2014 1
2015 1
2016 1
2017 1
2020 4
2021 1
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
TAS-102 and the quest for predictive biomarkers.
van der Velden DL, Opdam FL, Opdam FL. van der Velden DL, et al. Among authors: opdam fl. ESMO Open. 2017 Sep 21;2(4):e000263. doi: 10.1136/esmoopen-2017-000263. eCollection 2017. ESMO Open. 2017. PMID: 29018579 Free PMC article. No abstract available.
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
Postel-Vinay S, Lam VK, Ros W, Bauer TM, Hansen AR, Cho DC, Stephen Hodi F, Schellens JHM, Litton JK, Aspeslagh S, Autio KA, Opdam FL, McKean M, Somaiah N, Champiat S, Altan M, Spreafico A, Rahma O, Paul EM, Ahlers CM, Zhou H, Struemper H, Gorman SA, Watmuff M, Yablonski KM, Yanamandra N, Chisamore MJ, Schmidt EV, Hoos A, Marabelle A, Weber JS, Heymach JV. Postel-Vinay S, et al. Among authors: opdam fl. J Immunother Cancer. 2023 Mar;11(3):e005301. doi: 10.1136/jitc-2022-005301. J Immunother Cancer. 2023. PMID: 36927527 Free PMC article. Clinical Trial.
WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study.
Embaby A, Kutzera J, Geenen JJ, Pluim D, Hofland I, Sanders J, Lopez-Yurda M, Beijnen JH, Huitema ADR, Witteveen PO, Steeghs N, van Haaften G, van Vugt MATM, de Ridder J, Opdam FL. Embaby A, et al. Among authors: opdam fl. Gynecol Oncol. 2023 Jul;174:239-246. doi: 10.1016/j.ygyno.2023.05.063. Epub 2023 May 24. Gynecol Oncol. 2023. PMID: 37236033 Clinical Trial.
Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions.
Schutte T, Zeverijn LJ, Geurts BS, de Wit GF, Kok M, Opdam FL. Schutte T, et al. Among authors: opdam fl. Oncologist. 2023 Jul 5;28(7):e493-e497. doi: 10.1093/oncolo/oyad092. Oncologist. 2023. PMID: 37086483 Free PMC article.
Breath tests to phenotype drug disposition in oncology.
Opdam FL, Modak AS, Gelderblom H, Guchelaar HJ. Opdam FL, et al. Clin Pharmacokinet. 2013 Nov;52(11):919-26. doi: 10.1007/s40262-013-0099-9. Clin Pharmacokinet. 2013. PMID: 23868281 Review.
Phenotyping drug disposition in oncology.
Opdam FL, Gelderblom H, Guchelaar HJ. Opdam FL, et al. Cancer Treat Rev. 2012 Oct;38(6):715-25. doi: 10.1016/j.ctrv.2011.12.003. Epub 2012 Jan 4. Cancer Treat Rev. 2012. PMID: 22226243 Review.
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
Geurts BS, Battaglia TW, van Berge Henegouwen JM, Zeverijn LJ, de Wit GF, Hoes LR, van der Wijngaart H, van der Noort V, Roepman P, de Leng WWJ, Jansen AML, Opdam FL, de Jonge MJA, Cirkel GA, Labots M, Hoeben A, Kerver ED, Bins AD, Erdkamp FGL, van Rooijen JM, Houtsma D, Hendriks MP, de Groot JB, Verheul HMW, Gelderblom H, Voest EE. Geurts BS, et al. Among authors: opdam fl. BMC Cancer. 2023 Mar 4;23(1):205. doi: 10.1186/s12885-023-10663-2. BMC Cancer. 2023. PMID: 36870947 Free PMC article.
Lapatinib for advanced or metastatic breast cancer.
Opdam FL, Guchelaar HJ, Beijnen JH, Schellens JH. Opdam FL, et al. Oncologist. 2012;17(4):536-42. doi: 10.1634/theoncologist.2011-0461. Epub 2012 Apr 3. Oncologist. 2012. PMID: 22477724 Free PMC article. Review.
Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study).
Overbeek JK, Guchelaar NAD, Mohmaed Ali MI, Ottevanger PB, Bloemendal HJ, Koolen SLW, Mathijssen RHJ, Boere IA, Hamberg P, Huitema ADR, Sonke GS, Opdam FL, Ter Heine R, van Erp NP. Overbeek JK, et al. Among authors: opdam fl. Eur J Cancer. 2023 Nov;194:113346. doi: 10.1016/j.ejca.2023.113346. Epub 2023 Sep 19. Eur J Cancer. 2023. PMID: 37806255 Free article. Clinical Trial.
21 results